Literature DB >> 21864622

Evaluation of age-related differences in the immunogenicity of a G9 H9N2 influenza vaccine.

Robert L Atmar1, Wendy A Keitel, John M Quarles, Thomas R Cate, Shital M Patel, Diane Nino, Janet Wells, Nancy Arden, Kuo Guo, Heather Hill, Robert B Couch.   

Abstract

Avian influenza A/H9N2 viruses can infect people and are viruses considered to be a potential pandemic threat. Prior studies with an inactivated G1 clade H9N2 vaccine reported that persons born before 1968 were more likely to have an immune response than younger subjects. We performed a randomized, double-blind trial to evaluate whether immune responses following immunization with an inactivated, unadjuvanted influenza G9 H9N2 vaccine prepared from A/chicken/Hong Kong/G9/97 virus were more frequent in persons born in 1964 or earlier (44-59 years) than in those born in 1970 or later (18-38 years). One hundred twenty one persons were randomized to receive two doses of either 7.5- or 30-mcg of hemagglutinin intramuscularly. Post-vaccination serum antibody responses as measured by hemagglutination inhibition and microneutralization were either similar in the two age cohorts or greater in the younger age group. Persons born before 1968 were not more likely to respond to a G9 H9N2 influenza vaccine than persons born in 1970 or later.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21864622      PMCID: PMC3196602          DOI: 10.1016/j.vaccine.2011.08.044

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  22 in total

1.  Safety and cross-reactive immunogenicity of candidate AS03-adjuvanted prepandemic H5N1 influenza vaccines: a randomized controlled phase 1/2 trial in adults.

Authors:  Joanne M Langley; Louise Frenette; Linda Ferguson; Dennis Riff; Eric Sheldon; George Risi; Casey Johnson; Ping Li; Richard Kenney; Bruce Innis; Louis Fries
Journal:  J Infect Dis       Date:  2010-06-01       Impact factor: 5.226

2.  Safety and immunogenicity of nonadjuvanted and MF59-adjuvanted influenza A/H9N2 vaccine preparations.

Authors:  Robert L Atmar; Wendy A Keitel; Shital M Patel; Jacqueline M Katz; Dewei She; Hana El Sahly; Justine Pompey; Thomas R Cate; Robert B Couch
Journal:  Clin Infect Dis       Date:  2006-09-25       Impact factor: 9.079

3.  Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomised controlled trial.

Authors:  Isabel Leroux-Roels; Astrid Borkowski; Thomas Vanwolleghem; Mamadou Dramé; Frédéric Clement; Eliane Hons; Jeanne-Marie Devaster; Geert Leroux-Roels
Journal:  Lancet       Date:  2007-08-18       Impact factor: 79.321

4.  Safety and immunogenicity of whole-virus, alum-adjuvanted whole-virus, virosomal, and whole-virus intradermal influenza A/H9N2 vaccine formulations.

Authors:  Karl G Nicholson; Catherine I Thompson; Jaco M Klap; John M Wood; Sally Batham; Robert W Newman; Robert Mischler; Maria C Zambon; Iain Stephenson
Journal:  Vaccine       Date:  2009-09-30       Impact factor: 3.641

5.  Heterosubtypic neutralizing antibodies are produced by individuals immunized with a seasonal influenza vaccine.

Authors:  Davide Corti; Amorsolo L Suguitan; Debora Pinna; Chiara Silacci; Blanca M Fernandez-Rodriguez; Fabrizia Vanzetta; Celia Santos; Catherine J Luke; Fernando J Torres-Velez; Nigel J Temperton; Robin A Weiss; Federica Sallusto; Kanta Subbarao; Antonio Lanzavecchia
Journal:  J Clin Invest       Date:  2010-04-12       Impact factor: 14.808

6.  Safety of high doses of influenza vaccine and effect on antibody responses in elderly persons.

Authors:  Wendy A Keitel; Robert L Atmar; Thomas R Cate; Nancy J Petersen; Stephen B Greenberg; Fred Ruben; Robert B Couch
Journal:  Arch Intern Med       Date:  2006-05-22

7.  Vaccination with a synthetic peptide from the influenza virus hemagglutinin provides protection against distinct viral subtypes.

Authors:  Taia T Wang; Gene S Tan; Rong Hai; Natalie Pica; Lily Ngai; Damian C Ekiert; Ian A Wilson; Adolfo García-Sastre; Thomas M Moran; Peter Palese
Journal:  Proc Natl Acad Sci U S A       Date:  2010-10-18       Impact factor: 11.205

8.  A live attenuated H9N2 influenza vaccine is well tolerated and immunogenic in healthy adults.

Authors:  Ruth A Karron; Karen Callahan; Catherine Luke; Bhagvanji Thumar; Josephine McAuliffe; Elizabeth Schappell; Tomy Joseph; Kathleen Coelingh; Hong Jin; George Kemble; Brian R Murphy; Kanta Subbarao
Journal:  J Infect Dis       Date:  2009-03-01       Impact factor: 5.226

Review 9.  Seasonal inactivated influenza virus vaccines.

Authors:  Robert B Couch
Journal:  Vaccine       Date:  2008-09-12       Impact factor: 3.641

10.  Broad Clade 2 cross-reactive immunity induced by an adjuvanted clade 1 rH5N1 pandemic influenza vaccine.

Authors:  Isabel Leroux-Roels; Roger Bernhard; Pascal Gérard; Mamadou Dramé; Emmanuel Hanon; Geert Leroux-Roels
Journal:  PLoS One       Date:  2008-02-27       Impact factor: 3.240

View more
  7 in total

1.  Phase I/II randomized double-blind study of the safety and immunogenicity of a nonadjuvanted vero cell culture-derived whole-virus H9N2 influenza vaccine in healthy adults.

Authors:  Gerald Aichinger; Barbara Grohmann-Izay; Maikel V W van der Velden; Sandor Fritsch; Manuela Koska; Daniel Portsmouth; Mary Kate Hart; Wael El-Amin; Otfried Kistner; P Noel Barrett
Journal:  Clin Vaccine Immunol       Date:  2014-10-29

2.  Reply to Pawar et al.

Authors:  Stacy Todd; Erwin De Bruin; Nguyen Thi Duy Nhat; Marion Koopmans; Maciej F Boni
Journal:  J Infect Dis       Date:  2014-01-22       Impact factor: 7.759

Review 3.  Progress towards the Development of a Universal Influenza Vaccine.

Authors:  Wen-Chien Wang; Ekramy E Sayedahmed; Suryaprakash Sambhara; Suresh K Mittal
Journal:  Viruses       Date:  2022-07-30       Impact factor: 5.818

4.  Seroprevalence of antibodies to avian influenza A (H5) and A (H9) viruses among market poultry workers, Hanoi, Vietnam, 2001.

Authors:  Timothy M Uyeki; Doan C Nguyen; Thomas Rowe; Xiuhua Lu; Jean Hu-Primmer; Lien P Huynh; Nguyen L K Hang; Jacqueline M Katz
Journal:  PLoS One       Date:  2012-08-21       Impact factor: 3.240

5.  Broadly protective adenovirus-based multivalent vaccines against highly pathogenic avian influenza viruses for pandemic preparedness.

Authors:  Sai V Vemula; Yadvinder S Ahi; Anne-Marie Swaim; Jacqueline M Katz; Ruben Donis; Suryaprakash Sambhara; Suresh K Mittal
Journal:  PLoS One       Date:  2013-04-30       Impact factor: 3.240

Review 6.  Vaccines for preventing influenza in healthy adults.

Authors:  Vittorio Demicheli; Tom Jefferson; Eliana Ferroni; Alessandro Rivetti; Carlo Di Pietrantonj
Journal:  Cochrane Database Syst Rev       Date:  2018-02-01

7.  Adenovirus vector-based multi-epitope vaccine provides partial protection against H5, H7, and H9 avian influenza viruses.

Authors:  Ahmed O Hassan; Omar Amen; Ekramy E Sayedahmed; Sai V Vemula; Samuel Amoah; Ian York; Shivaprakash Gangappa; Suryaprakash Sambhara; Suresh K Mittal
Journal:  PLoS One       Date:  2017-10-12       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.